These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22774402)

  • 21. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
    Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Thromb Haemost; 2010 Aug; 104(2):279-86. PubMed ID: 20508896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
    Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
    Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral hypoglycemics: increased postoperative mortality in coronary risk patients.
    Jeger RV; Seeberger MD; Keller U; Pfisterer ME; Filipovic M
    Cardiology; 2007; 107(4):296-301. PubMed ID: 17264509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
    Christiaens L; Ragot S; Mergy J; Allal J; Macchi L
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):235-9. PubMed ID: 18388505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.
    Postula M; Janicki PK; Rosiak M; Przybylkowski A; Kaplon-Cieslicka A; Grygorowicz T; Trzepla E; Filipiak KJ; Czlonkowski A; Opolski G
    Cardiol J; 2013; 20(2):170-7. PubMed ID: 23558875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
    Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28780510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery.
    Bach J; Kammerer I; Isgro F; Haubelt H; Vogt A; Saggau W; Hellstern P
    Platelets; 2009 May; 20(3):150-7. PubMed ID: 19437331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
    Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin resistance in patients with chronic renal failure.
    Tanrikulu AM; Ozben B; Koc M; Papila-Topal N; Ozben T; Caymaz O
    J Nephrol; 2011; 24(5):636-46. PubMed ID: 21279952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet dysfunction associated with insulin therapy in patients with type 2 diabetes: please do not throw the baby out with the bathwater!
    Scheen AJ; Legrand D
    J Am Coll Cardiol; 2007 Feb; 49(5):628; author reply 628-9. PubMed ID: 17276192
    [No Abstract]   [Full Text] [Related]  

  • 40. Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.
    Gurbel PA; Bliden KP; Antonino MJ; Gesheff T; Cummings CC; Dubois BV; Herzog WR; Tantry US
    Thromb Res; 2012 Jan; 129(1):1-2. PubMed ID: 21862113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.